

Formulary Updates

Standard Choice/Choice Quality Drug Formulary



Recent Drug Approvals: Most new drug products are nonformulary until reviewed by the Pharmacy and Therapeutics Committee Date

July 1 st - September 30 th 2024: Drug name (use)	Formulary Status/Notes
Afluria (Flu Vaccine)	Preferred- \$0
Austedo XR Titration Kit (Tardive Dyskinesia)	Non-formulary
Brimonidine Tartrate/Dorzolamide (Ophthalmic)	Non-formulary
Clobetasol Propionate (Ophthalmic Suspension)	Non-formulary
Corlanor (Cardiovascular)	Non-formulary
Entresto (Heart Failure)	Preferred, QL
Fluad (Flu Vaccine)	Preferred- \$0
Fluarix (Flu Vaccine)	Preferred- \$0
Flublok (Flu Vaccine)	Preferred- \$0
Flucelvax (Flu Vaccine)	Preferred- \$0
Flulaval (Flu Vaccine)	Preferred- \$0
Fluzone/ HD (Flu Vaccine)	Preferred- \$0
Ivabradine (Cardiovascular)	Nonpreferred, PA, QL
Lazcluze	Nonformulary
Livdelzi	Nonformulary
Livmarli	Nonpreferred, PA, QL
Lofexidine	Nonformulary (For IA,MN,WI plans)
Moderna (Covid Vaccine)	Preferred- \$0
Moxifloxacin-Bromfenac (Ophthalmic)	Non-formulary

Q2 4/1/24-6/30/2024

Quartz-branded health plans are offered by [ENTITY].

©2023 Quartz Health Solutions, Inc.

[QuartzBenefits.com](https://www.QuartzBenefits.com)

Formulary Updates

Standard Choice/Choice Quality Drug Formulary



Novavax (Covid Vaccine)	Preferred- \$0
Ohtuvayre (COPD)	Non-formulary
Onyda XR (Antihypertensive)	Non-formulary
Oxtellar XR (Antisiezure)	Non-formulary
Retevmo (Cancer)	Non-formulary
Scartrate Cream (Topical)	Non-formulary
Sofdra (Anticholinergic)	Non-formulary
Sunitinib Malate (Cancer)	Preferred, PA, QL, Specialty
Timolol/ Brimonidine Tartrate/Dorzolamide/Bimatoprost (Ophthalmic) (combo eye drops)	Non-formulary
Timolol/ Brimonidine Tartrate/Dorzolamide (Ophthalmic) (combo eye drops)	Non-formulary
Tryvio (Antihypertensive)	Non-formulary
Vafseo (Anemia)	Non-formulary
Veltassa (Hyperkalemia)	Nonpreferred, QL
Vigafyde (Anti-Siezure)	Non-formulary
Zoryve Cream (Skin conditions) Entresto	Non-formulary

Pharmacy and Therapeutics (P&T) Committee Formulary Changes:

7/16/2024 P&T meeting: Changes Effective 10/01/2024

Drug name (use)	Formulary Status/Notes
Clindamycin Phosphate-Benzoyl Peroxide Gel 1.2-2.5% (Acne)	Nonpreferred
Enoxaparin (Anticoagulant)	Preferred

Q2 4/1/24-6/30/2024

Quartz-branded health plans are offered by [ENTITY].

©2023 Quartz Health Solutions, Inc.

[QuartzBenefits.com](https://www.QuartzBenefits.com)

Formulary Updates

Standard Choice/Choice Quality Drug Formulary



Pharmacy and Therapeutics (P&T) Committee Formulary Changes:

7/16/2024 P&T meeting: Changes Effective 10/01/2024

Drug name (use)	Formulary Status/Notes
Firdapse	Nonpreferred, PA, QL increased
Fondaparinux (Anticoagulant)	Nonpreferred
Fragmin (Anticoagulant)	Preferred
Miebo (Ophthalmic)	Preferred
Vevye (Ophthalmic)	Nonformulary
Xiidra (Ophthalmic)	Preferred

New Generic Drugs: The brand equivalent is nonformulary once and FDA approve generic is available. Unless other wise noted on the formulary

July 1st– September 30th 2024

New Generic Drug name (use)	Brand Equivalent	Formulary Status/Notes
Dabigatran (Anticoagulant)	Pradaxa	Nonpreferred, QL
Ivabradine (Cardiovascular)	Corlanor	Nonpreferred, PA, QL
Tazarotene Cream, (0.05%) (Acne)	Tazorac	Preferred, PA